Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Removes Ciphergen from Biotech Index

NEW YORK, Nov. 14 (GenomeWeb News) - Ciphergen Biosystems has been removed from the Nasdaq Biotechnology Index as part of an semi-annual update, the exchange said today.

 

The index, which can be seen here, currently lists 152 companies. As part of the re-ranking, seven will be removed and 17 added. The changes take effect at the start of trading on Monday, Nov. 21.

 

The exchange updates NBI semi-annually, in May and November. Securities must meet the maintenance criteria of $100 million in market capitalization and 50,000 shares average daily trading volume to remain in the index. Securities missing the criteria for two consecutive rankings are removed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant, Science paper finds.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.